Aldeyra Therapeutics, Inc.
ALDX
$1.51
-$0.03-1.95%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 108.04% | -51.90% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 64.95% | -46.81% | |||
| Operating Income | -64.95% | 46.81% | |||
| Income Before Tax | -57.86% | 46.57% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -57.86% | 46.57% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -57.86% | 46.57% | |||
| EBIT | -64.95% | 46.81% | |||
| EBITDA | -66.07% | 47.29% | |||
| EPS Basic | -58.04% | 46.74% | |||
| Normalized Basic EPS | -57.82% | 46.65% | |||
| EPS Diluted | -58.04% | 46.74% | |||
| Normalized Diluted EPS | -57.82% | 46.65% | |||
| Average Basic Shares Outstanding | 0.00% | 0.26% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.26% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||